{"success":true,"data":{"pressRelease":{"id":"152653","rtpr_id":"nGNX4llXY0-20260924","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX Investors: Beta Bionics, Inc.  Shares Declined By $11.85 On January 9, 2026 -- Contact Kirby McInerney LLP to Discuss Your Rights","author":"Globe Newswire","published_at":"2026-09-24T22:00:00.098Z","article_body":"NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on\nyour Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ:\nBBNX) investment, contact Lauren Molinaro\n(https://www.globenewswire.com/Tracker?data=FAVtvaakYrSqOCoIhtY_cVOKFHyiwdSv_fHiGXRBRM4mmI95uPv3ROxWE9Hd9JP7Lo4xAqBE_tC-Gv6k0sP5BJRVn7VID4yD53QstEVmFXbbhD9XtZ2imRRkdMcw3_9C)\nof Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the\ncontact form below to discuss your rights or interests in the securities fraud\nclass action lawsuit at no cost. Investors have until November 3, 2026 to ask\nthe Court to appoint them as lead plaintiff.\n\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS\n(https://www.globenewswire.com/Tracker?data=VKuY-AOw74qYkXpcSE0Xyan8cz7DowxLIQZvdb5MWxqmbAm-1sZzL0YzN67lK9cVNsJjuru6pMPhqpaOdIDDdQRnNcgQUyUo2PKbQt3hrJCEl8zBW9lSJr1-Yvn3eq8HoQpsFBVCQqTAALollI_5XShnQEFEoZpi66ytQ8ecP7M=)]\n\nWhat Is The Lawsuit About?\n\nThe lawsuit has been filed on behalf of investors who purchased securities\nduring the period of July 30, 2025 through February 24, 2026, inclusive\n(“the Class Period”). The lawsuit alleges that Beta Bionics made false\nand/or misleading statements and failed to disclose to investors that: (i) the\nCompany’s iLet Bionic Pancreas insulin pump (“iLet”) was malfunctioning\nand dosing patients with dangerously high levels of insulin, causing\nhypoglycemic events; (ii) the FDA had raised these issues in a Form 483 it\nsent to Beta Bionics; (iii) there were thousands of customer complaints\nback-filed with the FDA in response to the Form 483, including hundreds of\nlife-threatening events requiring significant medical intervention; and (iv)\nthe FDA was not satisfied with the Company’s response to the issue, as Beta\nBionics had failed to implement meaningful corrective actions.\n\nOn January 8, 2026, Beta Bionics reported its fourth quarter 2025 earnings\nresults, revealing an unexpected miss on new iLet patient starts. On this\nnews, Beta Bionics’ stock price dropped $11.85, or 37%, to close at $20.14\nper share on January 9, 2026.\n\nOn January 30, 2026, Beta Bionics filed a Form 8-K with the U.S. Securities &\nExchange Commission, revealing that the FDA had sent the Company a warning\nletter connected to its earlier Form 483. The Company revealed that the\nFDA’s concerns were more serious than they had previously acknowledged, and\nthat the FDA took issue with Beta Bionics’ quality management system for\niLet and the Company’s failure to take corrective action based on the Form\n483. On this news, Beta Bionics’ stock price fell $0.96, or 6.5%, to close\nat $13.83 per share on January 30, 2026.\n\nThen, on February 24, 2026, the FDA publicly released its warning letter,\nrevealing the FDA’s concerns with iLet’s underlying issues and stating\nthat any iLet malfunction or hypoglycemia requiring medical intervention must\nbe reported to the FDA. On this news, Beta Bionics’ stock price fell $0.50,\nor 3.7%, to close at $12.89 per share on February 25, 2026.\n\n[CLICK HERE TO LEARN MORE ABOUT THE LAWSUIT\n(https://www.globenewswire.com/Tracker?data=bXzA4B7OpI0qkVChrJKAZ8nEb_h00FHswnKceR0fiPZcyXaa-sZZl0GEG-iO0sHTTauQyNY_xVszSW2-lvG7NmBICGTWFCI2rArCldyvik3YeAfr-2VQXqScA4K8J0j0AghH8PBdJw6OwcAHg15dUcaeZW1RG3-aA0qxmz1WENw=)]\n\nWhat Are My Options?\n\nCourts do not consider applications filed after the relevant deadline. The\nlead plaintiff oversees the litigation on behalf of the class and may\ninfluence key decisions, including litigation strategy and settlement. Courts\nregularly appoint individual investors as lead plaintiffs, not only\ninstitutions. Learn more about the lead plaintiff process and eligibility\nrequirements here\n(https://www.globenewswire.com/Tracker?data=1JBNFMmpVALT8jVNodbYE9of4uYUp_sPEu2DInUwP10j2lzMoh8VmM7cODpfTDz7kHi0UUF9x4YrscQMsWN1wEhTpiGXH51aZImU-LRXRgU=).\n\n[WHAT IS A SECURITIES CLASS ACTION?\n(https://www.globenewswire.com/Tracker?data=P3VCeAhVTx0AdQgbf6f6Zem_mhzDSn13zzwTNb_PqfV-RaX3f4oSdN-VF3wvJ_oPkvl5eyfgLjbSTsVoyRsADDfUzEHiOJYtr7r0DhBPs2u-N3VycxIl-yMJTstwN4jLWEgzAZeWawYsYe6vcacrCg==)]\n\nKirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=QF9_94UKzFIE0YLWYi5MruAjcZ0_vKVuBHvw4jjWXpFH6txlO4jgPHoJRmRWgdnHrn8gsINT-iTBzQxPQ9tpBl2ulx65DFIPXtr3Z_rcgX4=)\nis a New York-based plaintiffs’ law firm concentrating in securities,\nantitrust, whistleblower, and consumer litigation. The firm’s efforts on\nbehalf of shareholders in securities litigation have resulted in recoveries\ntotaling billions of dollars. Additional information about the firm can be\nfound at Kirby McInerney LLP’s website\n(https://www.globenewswire.com/Tracker?data=A5mREKjPoKuIZZoR2xmiWeiXTTxQqTzJe-_J6qGar5958QdBLn1u4Kf1_UYEasiN5HGkUYkNRJCwlIGQXFf2-Q==).\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\nKirby McInerney LLP        \nLauren Molinaro, Esq.\n212-699-1171\nhttps://www.kmllp.com\nhttps://securitiesleadplaintiff.com/\ninvestigations@kmllp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4llXY0-20260924","title":"BBNX Investors: Beta Bionics, Inc.  Shares Declined By $11.85 On January 9, 2026 -- Contact Kirby McInerney LLP to Discuss Your Rights","author":"Globe Newswire","ticker":"BBNX","created":"2026-09-24T22:00:00.098Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on\nyour Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ:\nBBNX) investment, contact Lauren Molinaro\n(https://www.globenewswire.com/Tracker?data=FAVtvaakYrSqOCoIhtY_cVOKFHyiwdSv_fHiGXRBRM4mmI95uPv3ROxWE9Hd9JP7Lo4xAqBE_tC-Gv6k0sP5BJRVn7VID4yD53QstEVmFXbbhD9XtZ2imRRkdMcw3_9C)\nof Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the\ncontact form below to discuss your rights or interests in the securities fraud\nclass action lawsuit at no cost. Investors have until November 3, 2026 to ask\nthe Court to appoint them as lead plaintiff.\n\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS\n(https://www.globenewswire.com/Tracker?data=VKuY-AOw74qYkXpcSE0Xyan8cz7DowxLIQZvdb5MWxqmbAm-1sZzL0YzN67lK9cVNsJjuru6pMPhqpaOdIDDdQRnNcgQUyUo2PKbQt3hrJCEl8zBW9lSJr1-Yvn3eq8HoQpsFBVCQqTAALollI_5XShnQEFEoZpi66ytQ8ecP7M=)]\n\nWhat Is The Lawsuit About?\n\nThe lawsuit has been filed on behalf of investors who purchased securities\nduring the period of July 30, 2025 through February 24, 2026, inclusive\n(“the Class Period”). The lawsuit alleges that Beta Bionics made false\nand/or misleading statements and failed to disclose to investors that: (i) the\nCompany’s iLet Bionic Pancreas insulin pump (“iLet”) was malfunctioning\nand dosing patients with dangerously high levels of insulin, causing\nhypoglycemic events; (ii) the FDA had raised these issues in a Form 483 it\nsent to Beta Bionics; (iii) there were thousands of customer complaints\nback-filed with the FDA in response to the Form 483, including hundreds of\nlife-threatening events requiring significant medical intervention; and (iv)\nthe FDA was not satisfied with the Company’s response to the issue, as Beta\nBionics had failed to implement meaningful corrective actions.\n\nOn January 8, 2026, Beta Bionics reported its fourth quarter 2025 earnings\nresults, revealing an unexpected miss on new iLet patient starts. On this\nnews, Beta Bionics’ stock price dropped $11.85, or 37%, to close at $20.14\nper share on January 9, 2026.\n\nOn January 30, 2026, Beta Bionics filed a Form 8-K with the U.S. Securities &\nExchange Commission, revealing that the FDA had sent the Company a warning\nletter connected to its earlier Form 483. The Company revealed that the\nFDA’s concerns were more serious than they had previously acknowledged, and\nthat the FDA took issue with Beta Bionics’ quality management system for\niLet and the Company’s failure to take corrective action based on the Form\n483. On this news, Beta Bionics’ stock price fell $0.96, or 6.5%, to close\nat $13.83 per share on January 30, 2026.\n\nThen, on February 24, 2026, the FDA publicly released its warning letter,\nrevealing the FDA’s concerns with iLet’s underlying issues and stating\nthat any iLet malfunction or hypoglycemia requiring medical intervention must\nbe reported to the FDA. On this news, Beta Bionics’ stock price fell $0.50,\nor 3.7%, to close at $12.89 per share on February 25, 2026.\n\n[CLICK HERE TO LEARN MORE ABOUT THE LAWSUIT\n(https://www.globenewswire.com/Tracker?data=bXzA4B7OpI0qkVChrJKAZ8nEb_h00FHswnKceR0fiPZcyXaa-sZZl0GEG-iO0sHTTauQyNY_xVszSW2-lvG7NmBICGTWFCI2rArCldyvik3YeAfr-2VQXqScA4K8J0j0AghH8PBdJw6OwcAHg15dUcaeZW1RG3-aA0qxmz1WENw=)]\n\nWhat Are My Options?\n\nCourts do not consider applications filed after the relevant deadline. The\nlead plaintiff oversees the litigation on behalf of the class and may\ninfluence key decisions, including litigation strategy and settlement. Courts\nregularly appoint individual investors as lead plaintiffs, not only\ninstitutions. Learn more about the lead plaintiff process and eligibility\nrequirements here\n(https://www.globenewswire.com/Tracker?data=1JBNFMmpVALT8jVNodbYE9of4uYUp_sPEu2DInUwP10j2lzMoh8VmM7cODpfTDz7kHi0UUF9x4YrscQMsWN1wEhTpiGXH51aZImU-LRXRgU=).\n\n[WHAT IS A SECURITIES CLASS ACTION?\n(https://www.globenewswire.com/Tracker?data=P3VCeAhVTx0AdQgbf6f6Zem_mhzDSn13zzwTNb_PqfV-RaX3f4oSdN-VF3wvJ_oPkvl5eyfgLjbSTsVoyRsADDfUzEHiOJYtr7r0DhBPs2u-N3VycxIl-yMJTstwN4jLWEgzAZeWawYsYe6vcacrCg==)]\n\nKirby McInerney LLP\n(https://www.globenewswire.com/Tracker?data=QF9_94UKzFIE0YLWYi5MruAjcZ0_vKVuBHvw4jjWXpFH6txlO4jgPHoJRmRWgdnHrn8gsINT-iTBzQxPQ9tpBl2ulx65DFIPXtr3Z_rcgX4=)\nis a New York-based plaintiffs’ law firm concentrating in securities,\nantitrust, whistleblower, and consumer litigation. The firm’s efforts on\nbehalf of shareholders in securities litigation have resulted in recoveries\ntotaling billions of dollars. Additional information about the firm can be\nfound at Kirby McInerney LLP’s website\n(https://www.globenewswire.com/Tracker?data=A5mREKjPoKuIZZoR2xmiWeiXTTxQqTzJe-_J6qGar5958QdBLn1u4Kf1_UYEasiN5HGkUYkNRJCwlIGQXFf2-Q==).\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and ethical rules.\n\nContacts\nKirby McInerney LLP        \nLauren Molinaro, Esq.\n212-699-1171\nhttps://www.kmllp.com\nhttps://securitiesleadplaintiff.com/\ninvestigations@kmllp.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-24T22:00:00.148770364Z","server_sent_at_ms":1790287200148},"received_at":"2026-09-24T22:00:00.201Z","source_url":null},"analysis":{"id":"141455","press_release_id":"152653","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["alleged iLet device malfunction causing hypoglycemic events and FDA Form 483 / warning letter","alleged failure to implement corrective actions on quality management system"],"eventType":"legal_litigation","narrative":"Kirby McInerney LLP issued a solicitation seeking a lead plaintiff for a securities fraud class action against Beta Bionics, with a November 3, 2026 deadline.\n\nThe suit covers purchasers from July 30, 2025 through February 24, 2026 and alleges Beta Bionics concealed iLet insulin pump malfunctions, an FDA Form 483, thousands of back-filed complaints, and inadequate corrective action.\n\nThis is law-firm marketing, not new issuer disclosure; the underlying FDA warning letter and stock declines were previously reported.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation restating known allegations -- suppress."},"keyFigures":{"customDimensions":{"class_period":"July 30, 2025 through February 24, 2026","jan_9_price_drop":"-$11.85 (-37%) to $20.14","feb_25_price_drop":"-$0.50 (-3.7%) to $12.89","jan_30_price_drop":"-$0.96 (-6.5%) to $13.83","lead_plaintiff_deadline":"November 3, 2026"}},"namedEntities":{"people":[{"name":"Lauren Molinaro","role":"attorney, Kirby McInerney LLP"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Kirby McInerney LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator referenced in allegations"}],"dollarAmounts":[{"amount":"$11.85","context":"BBNX share price decline on January 9, 2026"},{"amount":"$20.14","context":"closing price on January 9, 2026"},{"amount":"$0.96","context":"share price decline on January 30, 2026"},{"amount":"$13.83","context":"closing price on January 30, 2026"},{"amount":"$0.50","context":"share price decline on February 25, 2026"},{"amount":"$12.89","context":"closing price on February 25, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Kirby McInerney LLP seeking lead plaintiffs for a previously-disclosed securities class action. No new issuer disclosure, no certified class, no settlement."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kirby McInerney LLP issued a solicitation seeking a lead plaintiff for a securities fraud class action against Beta Bionics, with a November 3, 2026 deadline.\n\nThe suit covers purchasers from July 30, 2025 through February 24, 2026 and alleges Beta Bionics concealed iLet insulin pump malfunctions, an FDA Form 483, thousands of back-filed complaints, and inadequate corrective action.\n\nThis is law-firm marketing, not new issuer disclosure; the underlying FDA warning letter and stock declines were previously reported.","key_figures":{"customDimensions":{"class_period":"July 30, 2025 through February 24, 2026","jan_9_price_drop":"-$11.85 (-37%) to $20.14","feb_25_price_drop":"-$0.50 (-3.7%) to $12.89","jan_30_price_drop":"-$0.96 (-6.5%) to $13.83","lead_plaintiff_deadline":"November 3, 2026"}},"named_entities":{"people":[{"name":"Lauren Molinaro","role":"attorney, Kirby McInerney LLP"}],"products":["iLet Bionic Pancreas insulin pump"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"target of class action"},{"name":"Kirby McInerney LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulator referenced in allegations"}],"dollarAmounts":[{"amount":"$11.85","context":"BBNX share price decline on January 9, 2026"},{"amount":"$20.14","context":"closing price on January 9, 2026"},{"amount":"$0.96","context":"share price decline on January 30, 2026"},{"amount":"$13.83","context":"closing price on January 30, 2026"},{"amount":"$0.50","context":"share price decline on February 25, 2026"},{"amount":"$12.89","context":"closing price on February 25, 2026"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-24T22:00:05.417Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":5198,"modelName":"glm-5.3-flashx"}}